Panel to discuss new data regarding TP53 mutations and prostate cancer risk

“Our case discussion for January 18 is going to be focused on a patient who initially has biochemically recurrent prostate cancer [and] progresses to metastatic disease,” says Veda N. Giri, MD.

In this video, Veda N. Giri, MD, offers a preview of the ENGAGEMENT Study Virtual Genetics Board’s upcoming case discussion focusing on new data on TP53 mutations and prostate cancer risk as well as TP53-related management. which you can sign up for by going to www.prostategenetics.com/engagement. The event will take place on January 18 at 12 pm ET. Giri is a Professor in Medical Oncology and Cancer Biology at Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania.